Xenon Pharmaceuticals - Stock Price History | XENE

Historical daily share price chart and data for Xenon Pharmaceuticals since 2023 adjusted for splits. The latest closing stock price for Xenon Pharmaceuticals as of January 31, 2023 is 39.09.
  • The all-time high Xenon Pharmaceuticals stock closing price was 39.82 on August 24, 2022.
  • The Xenon Pharmaceuticals 52-week high stock price is 41.39, which is 5.9% above the current share price.
  • The Xenon Pharmaceuticals 52-week low stock price is 24.94, which is 36.2% below the current share price.
  • The average Xenon Pharmaceuticals stock price for the last 52 weeks is 33.86.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Xenon Pharmaceuticals Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2022 33.1731 31.5900 39.8200 25.0900 39.4300 26.22%
2021 20.7130 14.7400 35.4000 13.6500 31.2400 103.12%
2020 12.5954 13.7200 17.5700 8.0800 15.3800 17.32%
2019 9.5171 6.6800 14.6500 6.3900 13.1100 107.77%
2018 7.6217 2.8750 14.9000 2.7000 6.3100 123.36%
2017 4.3814 7.8500 9.8500 2.2000 2.8250 -63.31%
2016 7.4501 7.9600 8.5500 5.8800 7.7000 -4.23%
2015 12.6255 18.7000 23.0000 7.6900 8.0400 -59.29%
2014 14.6806 10.5000 19.9100 10.5000 19.7500 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.377B $0.018B
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.147B 9.34
GSK (GSK) United Kingdom $71.894B 8.95
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.086B 18.92
Ginkgo Bioworks Holdings (DNA) United States $3.531B 0.00
Myovant Sciences (MYOV) United Kingdom $2.613B 0.00
Arcus Biosciences (RCUS) United States $1.618B 24.29
Biohaven (BHVN) United States $1.266B 0.00
Emergent Biosolutions (EBS) United States $0.645B 5.07
ADC Therapeutics SA (ADCT) Switzerland $0.378B 0.00
Ambrx Biopharma (AMAM) United States $0.078B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00